Clinical Trial Update: Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating apatinib in combination with SHR-1210 for non-small-cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Lung Diseases, Neoplasms | Phase 1, Phase 2 | Status: UNKNOWN